Search Results

You searched for : BoehringerIngelheim

	Boehringer Ingelheim's Investigational Treatment for Schizophrenia receives FDA Breakthrough Therapy Designation The company also announced the planned initiation of the innovative CONNEX Phase III clinical trial program assessing the safety and efficacy of BI 425809 ... May 27
	New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1 New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1... Nov 07
	Alembic Pharma receives USFDA tentative approval for Empagliflozin and Linagliptin tablets Empagliflozin and Linagliptin tablets, have an estimated market size of US$ 244 million for twelve months ending June 2020... Aug 27
	Boehringer Ingelheim Acquires Northern Biologics, Expanding Immuno-oncology Portfolio Boehringer Ingelheim Acquires Northern Biologicsâ€™ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio ... May 16
	Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorisation for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (... Mar 03
	Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies ... Sep 21
6 Matching result(s) found!

-Advertisements-

Trending Now
	Maternal and Infant Health in Focus as India Observes World Health Day 2025April 05, 2025
	Under 15 Children Under Threat: The TB Comeback No One Saw Coming April 04, 2025
	MGM Healthcare Performs World's First Modified Multi-Visceral Transplant for Rare Intestinal DisorderApril 04, 2025
	World Health Day 2025: St. George’s University’s Role in Preparing Doctors to Tackle Global Health ChallengesApril 04, 2025
	Strength Doesn’t Retire: The Science Behind Ageless PowerApril 04, 2025
	Beyond the Baby Bump: Can Delayed Pregnancy Increase Autism Risk in ChildrenApril 04, 2025
	University of Manchester invites applications for MA Social AnthropologyApril 03, 2025
	Ahead of World Health Day, Sova Health Launches Advanced Microbiome Tests & Evidence-Based Precision Supplements April 03, 2025
	Half of women cannot make decisions about their reproductive health and bodily autonomyApril 03, 2025
	UGRO CAPITAL LIMITED PUBLIC ISSUE OF SECURED, RATED, LISTED, REDEEMABLE, NON-CONVERTIBLE DEBENTURES (SECURED NCDS) OPENS TODAY EFFECTIVE ANNUALIZED YIELD UP TO 11.01% PER ANNUM* April 03, 2025
	SF Airlines Entrusts Çelebi India with Freighter Handling at Kempegowda International Airport, BengaluruApril 03, 2025
	Is This the Future of Physiotherapy? Inside Stance Health’s $1M ExpansionApril 03, 2025
	The Daily Shower Debate: Are You Washing Away Your Skin’s Health?April 03, 2025
	The Digital Sleep Thief: How Night-time Screen Addiction is Robbing You of Bed-time RestApril 02, 2025
	KKR Launches ‘Knight Bite’ – A Digital Series That Serves Up Food, Fun, and Cricket!April 02, 2025
	Crompton rolls out its all new range of Aura, Avancer & Jedi Air Coolers for an effortless summer cooling experienceApril 02, 2025
	CARE Hospitals, Hi-Tech City Strengthens Orthopaedics Department with Renowned SurgeonsApril 02, 2025
	World Autism Awareness Day: Breaking the Chains of Stigma in IndiaApril 02, 2025
	From Scroll to Squint: How Reels Are Reshaping Your VisionApril 02, 2025
	Moscow Center for Diagnostics and Telemedicine Receives License for Radiology Residency ProgramApril 02, 2025

Search Results

Boehringer Ingelheim's Investigational Treatment for Schizophrenia receives FDA Breakthrough Therapy Designation

New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1

Alembic Pharma receives USFDA tentative approval for Empagliflozin and Linagliptin tablets

Boehringer Ingelheim Acquires Northern Biologics, Expanding Immuno-oncology Portfolio

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases

Trending Now